Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
NSABP P-1
About the Trial
The Breast Cancer Prevention Trial randomized 13,388 women at elevated breast cancer risk to 5 years of tamoxifen or placebo. Tamoxifen cut invasive breast cancer by 49 percent, an effect confined to estrogen receptor positive tumors. The price: more endometrial cancer and venous clots, especially in women over 50. The trial proved chemoprevention of a solid tumor was possible, a paradigm shift. It also popularized formal risk estimation with the Gail model. STAR later showed raloxifene matched prevention with less uterine cancer. Uptake stayed low due to side effect fears, but the concept now extends to aromatase inhibitors for postmenopausal women at high risk.
Related Trials
Diabetes Prevention Program
The DPP randomized 3,234 people with impaired glucose tolerance to metformin, intensive lifestyle modification, or placebo. Lifest...
LOOK AHEAD
LOOK AHEAD randomized over 5,100 overweight or obese adults with type 2 diabetes to intensive lifestyle intervention targeting 7 p...
WOSCOPS
The West of Scotland Coronary Prevention Study randomized 6,595 healthy men with elevated LDL cholesterol to pravastatin or placeb...
Heart Protection Study
HPS randomized 20,536 UK adults with vascular disease or diabetes to simvastatin 40 mg or placebo regardless of baseline cholester...